Parrish Galliher earned his B.A. degree in biology at Boston University and his M.S. degree in biochemical engineering at MIT. Galliher joined Biogen, Inc. in 1981 where he was responsible for design, commissioning and management of Biogen’s first biomanufacturing facilities for both E.coli and mammalian cell manufacturing. As Director of Process Engineering, he led the team responsible for startup, initial validation and commissioning of Biogen’s Avonex ® manufacturing facility, later licensed by the FDA. Galliher joined Alpha-Beta Technology (ABT) in 1994 as Director of Manufacturing Development and led the technology transfer, startup, validation, and commissioning of ABT’s 55,000 sq ft. biopharmaceutical manufacturing plant in Smithfield, RI at which he became Vice President of Operations and General Manager. Galliher joined LeukoSite, Inc. in 1999 as Vice President of Biologics Manufacturing and continued in that role after Millennium Pharmaceuticals acquired LeukoSite. At Millennium, Galliher led the CMC Team that contributed to FDA and EU licensure of CAMPATH ® monoclonal antibody.He also led the Biologics Manufacturing Productivity Improvement Program which enabled high speed development of Millennium’s monoclonal antibodies for clinical trials. In December 2002, Galliher became Founder, President and CEO of Xcellerex, an advanced technology contract biomanufacturing and disposable manufacturing systems company. In December 2004, Galliher transitioned to Founder, President and Chief Technology Officer of Xcellerex, Inc.. Galliher is co-inventor on numerous patents in the field of biomanufacturing.